期刊文献+

Endozepine-4 levels are increased in hepatic coma 被引量:2

Endozepine-4 levels are increased in hepatic coma
下载PDF
导出
摘要 AIM:To evaluate the serum levels of endozepine-4,their relation with ammonia serum levels,the grading of coma and the severity of cirrhosis,in patients with hepatic coma. METHODS:In this study we included 20 subjects with Hepatic coma,20 subjects with minimal hepatic encephalopathy(MHE) and 20 subjects control. All subjects underwent blood analysis,Child Pugh and Model for End- stage liver disease(MELD) assessment,endozepine-4 analysis. RESULTS:Subjects with hepatic coma showed significant difference in endozepine-4(P < 0.001) and NH3 levels(P < 0.001) compared both to MHE and controls patients. Between NH3 and endozepine-4 we observed a significant correlation(P = 0.009; Pearson correlation 0.570). There was a significant correlation between endozepine-4 and MELD(P = 0.017; Pearsoncorrelation = 0.529). In our study blood ammonia concentration was noted to be raised in patients with hepatic coma,with the highest ammonia levels being found in those who were comatose. We also found a high correlation between endozepine-4 and ammonia(P < 0.001). In patients with grade Ⅳ hepatic coma,endozepine levels were significantly higher compared to other groups. CONCLUSION:This study suggests that an increased level of endozepine in subjects with higher levels of MELD was observed. In conclusion,data concerning involvement of the GABA-ergic system in HE coma could be explained by stage-specific alterations. AIM:To evaluate the serum levels of endozepine-4,their relation with ammonia serum levels,the grading of coma and the severity of cirrhosis,in patients with hepatic coma. METHODS:In this study we included 20 subjects with Hepatic coma,20 subjects with minimal hepatic encephalopathy(MHE) and 20 subjects control. All subjects underwent blood analysis,Child Pugh and Model for End- stage liver disease(MELD) assessment,endozepine-4 analysis. RESULTS:Subjects with hepatic coma showed significant difference in endozepine-4(P < 0.001) and NH3 levels(P < 0.001) compared both to MHE and controls patients. Between NH3 and endozepine-4 we observed a significant correlation(P = 0.009; Pearson correlation 0.570). There was a significant correlation between endozepine-4 and MELD(P = 0.017; Pearsoncorrelation = 0.529). In our study blood ammonia concentration was noted to be raised in patients with hepatic coma,with the highest ammonia levels being found in those who were comatose. We also found a high correlation between endozepine-4 and ammonia(P < 0.001). In patients with grade Ⅳ hepatic coma,endozepine levels were significantly higher compared to other groups. CONCLUSION:This study suggests that an increased level of endozepine in subjects with higher levels of MELD was observed. In conclusion,data concerning involvement of the GABA-ergic system in HE coma could be explained by stage-specific alterations.
出处 《World Journal of Gastroenterology》 SCIE CAS 2015年第30期9103-9110,共8页 世界胃肠病学杂志(英文版)
关键词 Endozepine-4 HEPATIC ENCEPHALOPATHY HEPATIC COMA Cirrhosis BENZODIAZEPINE Peripheralbenzodiazepine receptor Model for End - stage liverdisease Glutamate-related NEUROTOXICITY which in turnmay alter the γ-aminobutyric acid Endozepine-4 Hepatic encephalopathy Hepatic coma Cirrhosis,Benzodiazepine Peripheral benzodiazepine receptor Model for End-stage liver disease Glutamate-related neurotoxicity which in turn may alter the γ-aminobutyric acid
  • 相关文献

参考文献48

  • 1Blei AT. Diagnosis and treatment of hepatic encephalopathy.Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 959-974[PMID: 11139349 DOI: 10.1053/bega.2000.0141]. 被引量:1
  • 2Malaguarnera M, Pistone G, Astuto M, Vecchio I, RaffaeleR, Lo Giudice E, Rampello L. Effects of L-acetylcarnitine oncirrhotic patients with hepatic coma: randomized double-blind,placebo-controlled trial. Dig Dis Sci 2006; 51: 2242-2247 [PMID:17080254 DOI: 10.1007/s10620-006-9187-0]. 被引量:1
  • 3Malaguarnera M, Risino C, Cammalleri L, Malaguarnera L,Astuto M, Vecchio I, Rampello L. Branched chain amino acidssupplemented with L-acetylcarnitine versus BCAA treatment inhepatic coma: a randomized and controlled double blind study.Eur J Gastroenterol Hepatol 2009; 21: 762-770 [PMID: 19357525DOI: 10.1097/MEG.0b013e328309c791]. 被引量:1
  • 4Donovan JP, Schafer DF, Shaw BW, Sorrell MF. Cerebral oedemaand increased intracranial pressure in chronic liver disease. Lancet1998; 351: 719-721 [PMID: 9504517 DOI: 10.1016/S0140-6736(97)07373-X]. 被引量:1
  • 5Malaguarnera M, Vacante M, Russo C, Gargante MP, GiordanoM, Bertino G, Neri S, Malaguarnera M, Galvano F, Li Volti G.Rosuvastatin reduces nonalcoholic fatty liver disease in patientswith chronic hepatitis C treated with α-interferon and ribavirin:Rosuvastatin reduces NAFLD in HCV patients. Hepat Mon 2011;11: 92-98 [PMID: 22087124]. 被引量:1
  • 6Malaguarnera M, Drago F, Malaguarnera G, Li Volti G, SalomoneS, Caraci F, Galvano F, Vacante M, Bucolo C, Malaguarnera M.Metal fume fever. Lancet 2013; 381: 2298 [PMID: 23809563 DOI:10.1016/S0140-6736(13)60689-3]. 被引量:1
  • 7Baraldi M. Supersensitivity of GABA-A receptors in hepaticencephalopathy. Neurochem Res 1990; 15: 153-160 [PMID:2159120 DOI: 10.1007/BF00972205]. 被引量:1
  • 8Baraldi M, Avallone R, Corsi L, Venturini I, Baraldi C, ZeneroliML. Natural endogenous ligands for benzodiazepine receptors inhepatic encephalopathy. Metab Brain Dis 2009; 24: 81-93 [PMID:19082698 DOI: 10.1007/s11011-008-9111-8]. 被引量:1
  • 9Guidotti A, Forchetti CM, Corda MG, Konkel D, BennettCD, Costa E. Isolation, characterization, and purification tohomogeneity of an endogenous polypeptide with agonistic actionon benzodiazepine receptors. Proc Natl Acad Sci USA 1983; 80:3531-3535 [PMID: 6304714]. 被引量:1
  • 10Ball JA, Ghatei MA, Sekiya K, Krausz T, Bloom SR. Diazepambinding inhibitor-like immunoreactivity(51-70): distribution inhuman brain, spinal cord and peripheral tissues. Brain Res 1989;479: 300-305 [PMID: 2924161]. 被引量:1

同被引文献312

  • 1Yu-Jing Zhang.Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma[J].World Journal of Hepatology,2010,2(3):94-102. 被引量:1
  • 2Satarug, Soisungwan,Garrett, Scott H,Sens, Mary Ann,Sens, Donald A.Cadmium, Environmental Exposure, and Health Outcomes[J]. Environmental Health Perspectives . 2010 (2) 被引量:3
  • 3Virginia Hernandez–Gea,Sara Toffanin,Scott L. Friedman,Josep M. Llovet.Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma[J].Gastroenterology.2013(3) 被引量:6
  • 4Giovanna Fattovich,Tommaso Stroffolini,Irene Zagni,Francesco Donato.Hepatocellular carcinoma in cirrhosis: Incidence and risk factors[J].Gastroenterology.2004(5) 被引量:7
  • 5Gaetano Bertino,Isidoro Di Carlo,Annalisa Ardiri,Giuseppe Stefano Calvagno,Shirin Demma,Giulia Malaguarnera,Nicoletta Bertino,Mariano Malaguarnera,Adriana Toro,Michele Malaguarnera.Systemic therapies in hepatocellular carcinoma: present and future[J].Future Oncol.2013(10) 被引量:3
  • 6Igor P. Pogribny,Ivan Rusyn.Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma[J].Cancer Letters.2012 被引量:3
  • 7Gaetano Bertino,Annalisa Ardiri,Michele Malaguarnera,Giulia Malaguarnera,Nicoletta Bertino,Giuseppe Stefano Calvagno.Hepatocellualar Carcinoma Serum Markers[J].Seminars in Oncology.2012(4) 被引量:3
  • 8Manal M. Hassan,Lu-Yu Hwang,Chiq J. Hatten,Mark Swaim,Donghui Li,James L. Abbruzzese,Palmer Beasley,Yehuda Z. Patt.Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus[J]. Hepatology . 2002 (5) 被引量:2
  • 9Gaetano Bertino,Shirin Demma,Annalisa Ardiri,Maria Proiti,Salvatore Gruttadauria,Adriana Toro,Giulia Malaguarnera,Nicoletta Bertino,Michele Malaguarnera,Mariano Malaguarnera,Isidoro Di Carlo,Jingmin Zhao.Hepatocellular Carcinoma: Novel Molecular Targets in Carcinogenesis for Future Therapies[J]. BioMed Research International . 2014 被引量:1
  • 10Véronique Bouvard,Robert Baan,Kurt Straif,Yann Grosse,Béatrice Secretan,Fatiha El Ghissassi,Lamia Benbrahim-Tallaa,Neela Guha,Crystal Freeman,Laurent Galichet,Vincent Cogliano.A review of human carcinogens—Part B: biological agents[J]. Lancet Oncology . 2009 (4) 被引量:4

引证文献2

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部